Literature DB >> 10463486

Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.

W Hanna1, H J Kahn, M Trudeau.   

Abstract

Molecular alterations in breast cancer are being incorporated into the development of new treatment strategies. The HER-2/neu oncogene has been extensively investigated as a prognostic factor and recently as a predictor of response to chemotherapy or endocrine therapy. The development of a humanized anti-HER-2 monoclonal antibody (Herceptin) and the encouraging results obtained in the treatment of patients with HER-2 overexpressing metastatic breast cancer with this antibody have resulted in renewed interest in HER-2/neu. This article reviews the current knowledge of HER-2/neu both as a prognostic and a predictive factor. Problems associated with the standardization of the methodology for assessing HER-2/neu status and clinically significant cut-off points are addressed.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10463486

Source DB:  PubMed          Journal:  Mod Pathol        ISSN： 0893-3952            Impact factor:   7.842


  10 in total

1.  Correlation of the HER-2 protein expression and other clinicopathological features of ductal infiltrative breast cancer.

Authors:  Svjetlana Radović; Mirsad Babić; Mirsad Dorić; Edina Balta; Erol Kapetanović; Senad Secić
Journal:  Bosn J Basic Med Sci       Date:  2005-02       Impact factor: 3.363

2.  [Molecular protocol for HER2/neu analysis in breast carcinoma].

Authors:  Montse Verdú Artufel; Anna Colomer Valero; Ruth Román Lladó; Nadina Erill Sagalés; Miquel Calvo Llorca; Abelardo Moreno Carazo; Carlos Cordón Cardó; Xavier Puig Torrus
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

3.  The prognostic role of phospho-Src family kinase analysis in tongue cancer.

Authors:  Ofer Ben-Izhak; Victoria Cohen-Kaplan; Rafael M Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

4.  Identifying potential tumor markers and antigens by database mining and rapid expression screening.

Authors:  W T Loging; A Lal; I M Siu; T L Loney; C J Wikstrand; M A Marra; C Prange; D D Bigner; R L Strausberg; G J Riggins
Journal:  Genome Res       Date:  2000-09       Impact factor: 9.043

5.  The role of c-erbB-2 expression on the survival of patients with small-cell lung cancer.

Authors:  Ozlem Canoz; Metin Ozkan; Vedat Arsav; Ozlem Er; H Senol Coskun; Serdar Soyuer; Mustafa Altinbas
Journal:  Lung       Date:  2006 Sep-Oct       Impact factor: 2.584

6.  [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry].

Authors:  M Scheer; W Prange; K Petmecky; P Schirmacher; J E Zöller; A C Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  2003-03-07

7.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

8.  Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.

Authors:  Nidal M Almasri; Mohammad Al Hamad
Journal:  Breast Cancer Res       Date:  2005-05-24       Impact factor: 6.466

9.  HER2 gene status in primary breast cancers and matched distant metastases.

Authors:  Coya Tapia; Spasenija Savic; Urs Wagner; René Schönegg; Hedvika Novotny; Bruno Grilli; Michelle Herzog; Audrey Devito Barascud; Inti Zlobec; Gieri Cathomas; Luigi Terracciano; Georg Feichter; Lukas Bubendorf
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis.

Authors:  Farid Saleh; Suad Abdeen
Journal:  J Carcinog       Date:  2007-09-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.